Sage Therapeutics to Webcast R&D Day on December 13, 2016

CAMBRIDGE, Mass.--()--Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that it will webcast its R&D Day on Tuesday, December 13, 2016 from 12:30 p.m. to 3:30 p.m. ET in Boston, MA.

The event will highlight Sage’s R&D strategy, translational approaches and clinical development plans for SAGE-547 in super-refractory status epilepticus and postpartum depression, and for SAGE-217 in both mood and movement disorders.

In addition to presentations from members of the Sage management team, guest speakers include:

  • Eric Rosenthal, M.D., Associate Director, Neurosciences Intensive Care Unit; Director, Neurocritical Care Fellowship Program and Director, Critical Care Neuromonitoring at Massachusetts General Hospital
  • Samantha Meltzer-Brody, M.D., M.P.H., Associate Professor; Associate Chair for Faculty Development; and Director, Perinatal Psychiatry Program, University of North Carolina Center for Women's Mood Disorders

A live webcast of the presentations can be accessed on the investor page of Sage's website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage's website following the conference. A scientific poster exhibit will take place at 3:30 p.m. ET and will not be webcast.

About Sage Therapeutics

Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead compound, SAGE-547, is in Phase 3 clinical development for super-refractory status epilepticus, a rare and severe seizure disorder, and for postpartum depression. Sage is developing its next generation modulators, including SAGE-217 and SAGE-718, with a focus on acute and chronic CNS disorders.

Contacts

Investor Contact:
Sage Therapeutics
Paul Cox, 617-299-8377
paul.cox@sagerx.com
or
Media Contact:
Suda Communications LLC
Maureen L. Suda, 585-387-9248
maureen.suda@sagerx.com

Contacts

Investor Contact:
Sage Therapeutics
Paul Cox, 617-299-8377
paul.cox@sagerx.com
or
Media Contact:
Suda Communications LLC
Maureen L. Suda, 585-387-9248
maureen.suda@sagerx.com